Takeaways: Exdensur positions GSK as the first biologic in Canada with twice-yearly dosing for severe eosinophilic asthma, a major convenience advantage over existing IL‑4/5...
Home / SWIFT study
Browsing Tag: SWIFT study
Social Icons
Featured Posts
1
AbbVie’s Boey Approved in Canada for Glabellar Lines
June 24, 20262
Roche’s Itovebi Moves Closer to Public Access in Canada
June 24, 20263
